Market Overview

UPDATE: Piper Jaffray Upgrades BioDelivery Sciences International to Overweight on Checks

Related BDSI
Micro-Cap ETF And The Falling Greenback
BioDelivery Sciences Appoints Charles J. Bramlage And Dr. Barry I. Feinberg To Its Board Of Directors

Piper Jaffray upgraded BioDelivery Sciences International (NASDAQ: BDSI) from Neutral to Overweight and raised the price target from $5.00 to $8.00.

Piper Jaffray noted, "We continue to view BBCP as a valueadded offering for pain and expect the Phase III studies to prove positive based on revised trial designs. Most encouraging, in our view, was bioequivalence data for Bunavail, suggesting possible superiority to Suboxone. As a result of this and other diligence, we are adjusting our model to reflect the recently approved Suboxone generic but also a potential BNX advantage based on these data. Bunavail's NDA filing is planned for July and both BBCP Phase IIIs readout by YE13 or early 2014."

BioDelivery Sciences International closed at $4.05 on Friday.

Latest Ratings for BDSI

DateFirmActionFromTo
Oct 2014Roth CapitalDowngradesBuyNeutral
May 2014Summer StreetInitiates Coverage onBuy
Nov 2013Laidlaw & Co.Initiates Coverage onBuy

View More Analyst Ratings for BDSI
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Upgrades Analyst Ratings

 

Related Articles (BDSI)

Around the Web, We're Loving...

Get Benzinga's Newsletters